Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
- Previous Close
0.0970 - Open
0.0980 - Bid 0.0980 x --
- Ask 0.0988 x --
- Day's Range
0.0980 - 0.0980 - 52 Week Range
0.0775 - 0.4010 - Volume
331,650 - Avg. Volume
1,156,431 - Market Cap (intraday)
18.941M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.90
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.
www.lipigon.seRecent News: LPGO.ST
View MorePerformance Overview: LPGO.ST
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LPGO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LPGO.ST
View MoreValuation Measures
Market Cap
18.75M
Enterprise Value
8.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.52
Price/Book (mrq)
1.01
Enterprise Value/Revenue
0.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-245.57%
Return on Assets (ttm)
-69.50%
Return on Equity (ttm)
-139.56%
Revenue (ttm)
10.29M
Net Income Avi to Common (ttm)
-25.26M
Diluted EPS (ttm)
-0.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
11.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.34M